Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers

Neurotherapeutics

Volumn 13, Issue 1, 2016, Pages 190-191

  Møller, Rikke S ^a,b   Johannesen, Katrine M ^a,b  

^a DANISH EPILEPSY CENTRE   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; OXCARBAZEPINE; PHENYTOIN; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.6; NERVE PROTEIN;

ANTICONVULSANT THERAPY; ATAXIA; ATONIC SEIZURE; BRAIN DISEASE; CHOREOATHETOSIS; DEVELOPMENTAL DISORDER; DYSTONIA; EDITORIAL; EEG ABNORMALITY; ELECTROENCEPHALOGRAPHY; EPILEPTIC DISCHARGE; FOCAL EPILEPSY; GAIN OF FUNCTION MUTATION; GENE IDENTIFICATION; GENETIC COUNSELING; HUMAN; INTELLECTUAL IMPAIRMENT; MISSENSE MUTATION; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; MYOCLONUS SEIZURE; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; SCN8A ENCEPHALOPATHY; SUDDEN DEATH; TONIC CLONIC SEIZURE; TONIC SEIZURE; EPILEPSY;

BRAIN DISEASES; EPILEPSY; HUMANS; NERVE TISSUE PROTEINS; PRECISION MEDICINE; SODIUM CHANNEL BLOCKERS;

EID: 84955329488     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0403-5     Document Type: Editorial

References (11)

1. Veeramah KR, O’Brien JE, Meisler MH, et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet 2012;90:502-510.
2. Larsen J, Carvill GL, Gardella E, et al. The phenotypic spectrum of SCN8A encephalopathy. Neurology 2015;84:480-489.
3. Wagnon JL, Meisler MH. Recurrent and non-recurrent mutations of SCN8A in epileptic encephalopathy. Front Neurol 2015;6:104.
4. Blanchard MG, Willemsen MH, Walker JB, et al. De novo gain-of-function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy. J Med Genet 2015;52:330-337.
5. Estacion M, O'Brien JE, Conravey A, et al. A novel de novo mutation of SCN8A (Nav1.6) with enhanced channel activation in a child with epileptic encephalopathy. Neurobiol Dis 2014;69:117-123.
6. Takahashi S, Yamamoto S, Okayama A, et al. Electroclinical features of epileptic encephalopathy caused by SCN8A mutation. Pediatr Int 2015;57:758-762.
7. Kong W, Zhang Y, Gao Y, et al. SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability. Epilepsia 2015;56:431-438.
8. Ohba C, Kato M, Takahashi S, et al. Early onset epileptic encephalopathy caused by de novo SCN8A mutations. Epilepsia 2014; 55:994-1000.
9. Singh R, Jayapal S, Goyal S, et al. Early-onset movement disorder and epileptic encephalopathy due to de novo dominant SCN8A mutation. Seizure 2015;26:69-71.
10. Boerma RS, Braun KP, van de Broek MP, et al. Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach. Neurotherapeutics 2015.
11. Kuo CC, Chen RS, Lu L, et al. Carbamazepine inhibition of neuronal Na + currents: quantitative distinction from phenytoin and possible therapeutic implications. Mol Pharmacol 1997; 51:1077-1083.